Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

@article{Pergola2011BardoxoloneMA,
  title={Bardoxolone methyl and kidney function in CKD with type 2 diabetes.},
  author={Pablo E. Pergola and Philip Raskin and Robert Daniel Toto and Colin J. Meyer and Jesse W. Huff and Eric B. Grossman and Melissa Krauth and Stacey Ruiz and Paul K Audhya and Heidi Christ-Schmidt and Janet Wittes and David G. Warnock},
  journal={The New England journal of medicine},
  year={2011},
  volume={365 4},
  pages={327-36}
}
BACKGROUND Chronic kidney disease (CKD) associated with type 2 diabetes is the leading cause of kidney failure, with both inflammation and oxidative stress contributing to disease progression. Bardoxolone methyl, an oral antioxidant inflammation modulator, has shown efficacy in patients with CKD and type 2 diabetes in short-term studies, but longer-term effects and dose response have not been determined. METHODS In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 290 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Similar Papers

Loading similar papers…